Elsevier

The Lancet

Volume 361, Issue 9354, 25 January 2003, Pages 310-311
The Lancet

Research Letters
Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis

https://doi.org/10.1016/S0140-6736(03)12333-1Get rights and content

Summary

Calprotectin has been proposed as a useful marker of inflammatory bowel disease in children. We did a pilot study to establish whether it can be used to aid diagnosis of necrotising enterocolitis in preterm infants. Patients with clinical features of necrotising enterocolitis had raised faecal calprotectin concentrations at the time of diagnosis compared with matched controls (288·4 mg/L [SD 49·1] and 98·0 mg/L [60·6], respectively; p=0·0006). Faecal calprotectin might be a useful marker of gastrointestinal mucosal inflammation in neonates.

References (5)

There are more references available in the full text version of this article.

Cited by (102)

  • The Microbiome and Biomarkers for Necrotizing Enterocolitis: Are We Any Closer to Prediction?

    2017, Journal of Pediatrics
    Citation Excerpt :

    Isolated fecal calprotectin concentrations lack specificity for NEC diagnosis. with significant overlap of cases with healthy controls.21,85 Serum amyloid A (SAA), another acute-phase reactant, offered no advantage to urinary I-FABP and fecal calprotectin alone in discriminating NEC at first clinical signs from other entities.31

View all citing articles on Scopus
View full text